Breaking News, Collaborations & Alliances

Invenra, Xcellon Biologics Partner to Advance the Development of Multispecific ADCs

The partnership aims to accelerate the translation of bispecific and trispecific ADCs from discovery into preclinical and clinical development.

Author Image

By: Charlie Sternberg

Associate Editor

Invenra Inc., a U.S.-based biotechnology company pioneering multispecific antibody platform technologies, and Xcellon Biologics, a wholly owned subsidiary of Linden Lake Labs and a U.S.-based contract development and manufacturing organization (CDMO) specializing in antibody–drug conjugates (ADCs) and complex biologics, have joined forces to advance the development of multispecific ADCs. Under the collaboration, Invenra will leverage its proprietary B-Body Bispecific platform and T-Body Trisp...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters